Search

Your search keyword '"Fellah, Imen"' showing total 11 results
Start Over Author "Fellah, Imen" Search Limiters Full Text
11 results on '"Fellah, Imen"'

1. Calcification of surgical aortic bioprostheses and its impact on clinical outcome

Author

Guimbretière, Guillaume, primary, Sénage, Thomas, additional, Boureau, Anne-Sophie, additional, Roos, Jean-Charles, additional, Bernard, Quentin, additional, Carlier, Baptiste, additional, Veziers, Joelle, additional, Cueff, Caroline, additional, Piriou, Nicolas, additional, Coste, Guenola, additional, Fellah, Imen, additional, Lelarge, Coline, additional, Capoulade, Romain, additional, Jaafar, Philippe, additional, Manigold, Thibaud, additional, Letocart, Vincent, additional, Warin-Fresse, Karine, additional, Guérin, Patrice, additional, Costa, Cristina, additional, Vadori, Marta, additional, Galinañes, Manuel, additional, Manez, Rafael, additional, Soulillou, Jean-Paul, additional, Cozzi, Emanuele, additional, Padler-Karavani, Vered, additional, Serfaty, Jean-Michel, additional, Roussel, Jean-Christian, additional, and Le Tourneau, Thierry, additional

Published
2024
Full Text
View/download PDF

4. AORTLANTIC: French registry of aortic valve-sparing root replacement, preliminary multicentre results from western France

Author

Dubost, Clément, primary, Tomasi, Jacques, additional, Ducroix, Antoine, additional, Pluchon, Kevin, additional, Escrig, Pierre, additional, Fouquet, Olivier, additional, Aupart, Arthur, additional, Mirza, Alain, additional, Fellah, Imen, additional, Bezon, Eric, additional, Baufreton, Christophe, additional, El Arid, Jean Marc, additional, Roussel, Jean-Christian, additional, Verhoye, Jean-Philippe, additional, and Senage, Thomas, additional

Published
2022
Full Text
View/download PDF

5. MT9, a natural peptide from black mamba venom antagonizes the muscarinic type 2 receptor and reverses the M2R-agonist-induced relaxation in rat and human arteries

Author

Ciolek, Justyna, primary, Zoukimian, Claude, additional, Dhot, Justine, additional, Burban, Mélanie, additional, Triquigneaux, Mathilde, additional, Lauzier, Benjamin, additional, Guimbert, Christelle, additional, Boturyn, Didier, additional, Ferron, Marine, additional, Ciccone, Lidia, additional, Tepshi, Livia, additional, Stura, Enrico, additional, Legrand, Pierre, additional, Robin, Philippe, additional, Mourier, Gilles, additional, Schaack, Béatrice, additional, Fellah, Imen, additional, Blanchet, Guillaume, additional, Gauthier-Erfanian, Chantal, additional, Beroud, Rémy, additional, Servent, Denis, additional, De Waard, Michel, additional, and Gilles, Nicolas, additional

Published
2022
Full Text
View/download PDF

6. Enhanced Photocatalytic Kinetics Using HDTMA Coated TiO 2 -Smectite Composite for the Oxidation of Diclofenac under Solar Light.

Author

Fellah, Imen, Djellabi, Ridha, Ben Amor, Hédi, Hamdi, Noureddine, Ordonez, Marcela Frias, and Bianchi, Claudia L.

Subjects
*TITANIUM dioxide, *DICLOFENAC, *SURFACE interactions, *MONTMORILLONITE, *WATER pollution, *CRYSTAL surfaces
Abstract

Slow kinetics is one of the capital issues of photocatalytic technology because of its heterogeneous nature, which involves multi-step processes. Herein, we show that the simple modification of the sol-gel-based TiO2-smectite composite by hexadecyltrimethylammonium bromide (HDTMA) significantly boosts adsorption and photocatalytic efficient sol-gel-based light towards the removal of diclofenac from water. Three photocatalysts were prepared, including TiO2, TiO2-smectite, and HDTMA-TiO2-smectite. The materials were characterized to understand the surface interaction and crystal characteristics. In terms of photoactivity, it was found that the addition of HDTMA to TiO2-smectite improved the removal rate by twice. HDTMA changes the functional groups to TiO2-smectite composite allowing enhanced adsorption and photoactivity through the so-called Adsorb and Shuttle process. The recycling tests show that HDTMA-TiO2-smectite can be used up to four times with good performance. This modification approach could intensify the removal of pollutants from water instead of using complicated and costly techniques. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. Genetic association analyses highlight IL6, ALPL, and NAV1 as three new susceptibility genes underlying calcific aortic valve stenosis

Author

Cohorte D.E.S.I.R., Gaudreault, Nathalie, Dina, Christian, Thériault, Sébastien, Messika-Zeitoun, David, Arsenault, Benoit, Le Scouarnec, Solena, Capoulade, Romain, Boureau, Anne-Sophie, Bossé, Yohan, Rigade, Sidwell, Lamontagne, Maxime, Li, Zhonglin, Pibarot, Philippe, Simonet, Floriane, Clavel, Marie-Annick, Dagenais, François, Mathieu, Patrick, Lecointe, Simon, Baron, Estelle, Bonnaud, Stéphanie, Karakachoff, Matilde, Charpentier, Eric, Fellah, Imen, Roussel, Jean-Christian, Verhoye, Jean Philippe, Baufreton, Christophe, Probst, Vincent, Roussel, Ronan, Redon, Richard, Le Tourneau, Thierry, Schott, Jean-Jacques, Cohorte D.E.S.I.R., Gaudreault, Nathalie, Dina, Christian, Thériault, Sébastien, Messika-Zeitoun, David, Arsenault, Benoit, Le Scouarnec, Solena, Capoulade, Romain, Boureau, Anne-Sophie, Bossé, Yohan, Rigade, Sidwell, Lamontagne, Maxime, Li, Zhonglin, Pibarot, Philippe, Simonet, Floriane, Clavel, Marie-Annick, Dagenais, François, Mathieu, Patrick, Lecointe, Simon, Baron, Estelle, Bonnaud, Stéphanie, Karakachoff, Matilde, Charpentier, Eric, Fellah, Imen, Roussel, Jean-Christian, Verhoye, Jean Philippe, Baufreton, Christophe, Probst, Vincent, Roussel, Ronan, Redon, Richard, Le Tourneau, Thierry, and Schott, Jean-Jacques

Abstract

Background: Calcific aortic valve stenosis (CAVS) is a frequent and life-threatening cardiovascular disease for which there is currently no medical treatment available. To date, only 2 genes, LPA and PALMD, have been identified as causal for CAVS. We aimed to identify additional susceptibility genes for CAVS. Methods: A GWAS (genome-wide association study) meta-analysis of 4 cohorts, totaling 5115 cases and 354 072 controls of European descent, was performed. A TWAS (transcriptome-wide association study) was completed to integrate transcriptomic data from 233 human aortic valves. A series of post-GWAS analyses were performed, including fine-mapping, colocalization, phenome-wide association studies, pathway, and tissue enrichment as well as genetic correlation with cardiovascular traits. Results: In the GWAS meta-analysis, 4 loci achieved genome-wide significance, including 2 new loci: IL6 (interleukin 6) on 7p15.3 and ALPL (alkaline phosphatase) on 1p36.12. A TWAS integrating gene expression from 233 human aortic valves identified NAV1 (neuron navigator 1) on 1q32.1 as a new candidate causal gene. The CAVS risk alleles were associated with higher mRNA expression of NAV1 in valve tissues. Fine-mapping identified rs1800795 as the most likely causal variant in the IL6 locus. The signal identified colocalizes with the expression of the IL6 RNA antisense in various tissues. Phenome-wide association analyses in the UK Biobank showed colocalized associations between the risk allele at the IL6 lead variant and higher eosinophil count, pulse pressure, systolic blood pressure, and carotid artery procedures, implicating modulation of the IL6 pathways. The risk allele at the NAV1 lead variant colocalized with higher pulse pressure and higher prevalence of carotid artery stenosis. Association results at the genome-wide scale indicated genetic correlation between CAVS, coronary artery disease, and cardiovascular risk factors. Conclusions: Our study implicates 3 new genetic loci i

Published
2020

8. Genetic association analyses highlight IL6, ALPL, and NAV1 as three new susceptibility genes underlying calcific aortic valve stenosis

Author

Cohorte D.E.S.I.R., Thériault, Sébastien, Dina, Christian, Messika-Zeitoun, David, Le Scouarnec, Solena, Capoulade, Romain, Gaudreault, Nathalie, Rigade, Sidwell, Li, Zhonglin, Simonet, Floriane, Lamontagne, Maxime, Clavel, Marie-Annick, Arsenault, Benoit, Boureau, Anne-Sophie, Lecointe, Simon, Baron, Estelle, Bonnaud, Stéphanie, Karakachoff, Matilde, Charpentier, Eric, Fellah, Imen, Roussel, Jean-Christian, Verhoye, Jean Philippe, Baufreton, Christophe, Probst, Vincent, Roussel, Ronan, Redon, Richard, Dagenais, François, Pibarot, Philippe, Mathieu, Patrick, Le Tourneau, Thierry, Bossé, Yohan, Schott, Jean-Jacques, Cohorte D.E.S.I.R., Thériault, Sébastien, Dina, Christian, Messika-Zeitoun, David, Le Scouarnec, Solena, Capoulade, Romain, Gaudreault, Nathalie, Rigade, Sidwell, Li, Zhonglin, Simonet, Floriane, Lamontagne, Maxime, Clavel, Marie-Annick, Arsenault, Benoit, Boureau, Anne-Sophie, Lecointe, Simon, Baron, Estelle, Bonnaud, Stéphanie, Karakachoff, Matilde, Charpentier, Eric, Fellah, Imen, Roussel, Jean-Christian, Verhoye, Jean Philippe, Baufreton, Christophe, Probst, Vincent, Roussel, Ronan, Redon, Richard, Dagenais, François, Pibarot, Philippe, Mathieu, Patrick, Le Tourneau, Thierry, Bossé, Yohan, and Schott, Jean-Jacques

Abstract

Background: Calcific aortic valve stenosis (CAVS) is a frequent and life-threatening cardiovascular disease for which there is currently no medical treatment available. To date, only 2 genes, LPA and PALMD, have been identified as causal for CAVS. We aimed to identify additional susceptibility genes for CAVS. Methods: A GWAS (genome-wide association study) meta-analysis of 4 cohorts, totaling 5115 cases and 354 072 controls of European descent, was performed. A TWAS (transcriptome-wide association study) was completed to integrate transcriptomic data from 233 human aortic valves. A series of post-GWAS analyses were performed, including fine-mapping, colocalization, phenome-wide association studies, pathway, and tissue enrichment as well as genetic correlation with cardiovascular traits. Results: In the GWAS meta-analysis, 4 loci achieved genome-wide significance, including 2 new loci: IL6 (interleukin 6) on 7p15.3 and ALPL (alkaline phosphatase) on 1p36.12. A TWAS integrating gene expression from 233 human aortic valves identified NAV1 (neuron navigator 1) on 1q32.1 as a new candidate causal gene. The CAVS risk alleles were associated with higher mRNA expression of NAV1 in valve tissues. Fine-mapping identified rs1800795 as the most likely causal variant in the IL6 locus. The signal identified colocalizes with the expression of the IL6 RNA antisense in various tissues. Phenome-wide association analyses in the UK Biobank showed colocalized associations between the risk allele at the IL6 lead variant and higher eosinophil count, pulse pressure, systolic blood pressure, and carotid artery procedures, implicating modulation of the IL6 pathways. The risk allele at the NAV1 lead variant colocalized with higher pulse pressure and higher prevalence of carotid artery stenosis. Association results at the genome-wide scale indicated genetic correlation between CAVS, coronary artery disease, and cardiovascular risk factors. Conclusions: Our study implicates 3 new genetic loci i

Published
2019

9. Genetic Association Analyses Highlight IL6 , ALPL , and NAV1 As 3 New Susceptibility Genes Underlying Calcific Aortic Valve Stenosis

Author

Thériault, Sébastien, primary, Dina, Christian, additional, Messika-Zeitoun, David, additional, Le Scouarnec, Solena, additional, Capoulade, Romain, additional, Gaudreault, Nathalie, additional, Rigade, Sidwell, additional, Li, Zhonglin, additional, Simonet, Floriane, additional, Lamontagne, Maxime, additional, Clavel, Marie-Annick, additional, Arsenault, Benoit J., additional, Boureau, Anne-Sophie, additional, Lecointe, Simon, additional, Baron, Estelle, additional, Bonnaud, Stéphanie, additional, Karakachoff, Matilde, additional, Charpentier, Eric, additional, Fellah, Imen, additional, Roussel, Jean-Christian, additional, Philippe Verhoye, Jean, additional, Baufreton, Christophe, additional, Probst, Vincent, additional, Roussel, Ronan, additional, Redon, Richard, additional, Dagenais, François, additional, Pibarot, Philippe, additional, Mathieu, Patrick, additional, Le Tourneau, Thierry, additional, Bossé, Yohan, additional, Schott, Jean-Jacques, additional, Balkau, B., additional, Ducimetière, P., additional, Eschwège, E., additional, Alhenc-Gelas, F., additional, Girault, A., additional, Fumeron, F., additional, Marre, M., additional, Bonnet, F., additional, Bonnefond, A., additional, Froguel, P., additional, Rancière, F., additional, Cogneau, J., additional, Born, C., additional, Caces, E., additional, Cailleau, M., additional, Lantieri, O, additional, Moreau, J.G., additional, Rakotozafy, F., additional, Tichet, J., additional, and Vol, S., additional

Published
2019
Full Text
View/download PDF

10. Features of Herpesviruses (CMV, EBV, HHV6) Infections and Immune Reconstitution after Allogeneic Stem Cell Transplantation (allo-SCT) Using Alternative Donors: Comparison Between Matched Unrelated Donors (MUD) and Cord Blood (CB) as Stem Cell Source.

Author

Chevallier, Patrice, primary, Guillaume, Thierry, primary, Planche, Lucie, primary, Hebia-Fellah, Imen, primary, Bodin, Celine Bressollette-, primary, Rialland, Fanny, primary, Coste-Burel, Marianne, primary, Ayari, Sameh, primary, Delaunay, Jacques, primary, Horvais, Valerie, primary, Harousseau, Jean-Luc, primary, Mohty, Mohamad, primary, and Imbert-Marcille, Berthe-Marie, primary

Published
2008
Full Text
View/download PDF

11. Calcification of surgical aortic bioprostheses and its impact on clinical outcome.

Author

Guimbretière G, Sénage T, Boureau AS, Roos JC, Bernard Q, Carlier B, Veziers J, Cueff C, Piriou N, Coste G, Fellah I, Lelarge C, Capoulade R, Jaafar P, Manigold T, Letocart V, Warin-Fresse K, Guérin P, Costa C, Vadori M, Galinañes M, Manez R, Soulillou JP, Cozzi E, Padler-Karavani V, Serfaty JM, Roussel JC, and Le Tourneau T

Subjects
Humans, Male, Female, Aged, Retrospective Studies, Aortic Valve Stenosis surgery, Aortic Valve Stenosis diagnostic imaging, Heart Valve Prosthesis Implantation methods, Prognosis, Treatment Outcome, Postoperative Complications diagnostic imaging, Bioprosthesis, Aortic Valve diagnostic imaging, Aortic Valve surgery, Aortic Valve pathology, Calcinosis diagnostic imaging, Calcinosis surgery, Heart Valve Prosthesis, Tomography, X-Ray Computed methods
Abstract

Aims: Aortic valve calcification (AVC) of surgical valve bioprostheses (BPs) has been poorly explored. We aimed to evaluate in vivo and ex vivo BP AVCs and its prognosis value., Methods and Results: Between 2011 and 2019, AVC was assessed using in vivo computed tomography (CT) in 361 patients who had undergone surgical valve replacement 6.4 ± 4.3 years earlier. Ex vivo CT scans were performed for 37 explanted BPs. The in vivo CT scans were interpretable for 342 patients (19 patients [5.2%] were excluded). These patients were 77.2 ± 9.1 years old, and 64.3% were male. Mean in vivo AVC was 307 ± 500 Agatston units (AU). The AVC was 562 ± 570 AU for the 183 (53.5%) patients with structural valve degeneration (SVD) and 13 ± 43 AU for those without SVD (P < 0.0001). In vivo and ex vivo AVCs were strongly correlated (r = 0.88, P < 0.0001). An in vivo AVC > 100 AU (n = 147, 43%) had a specificity of 96% for diagnosing Stage 2-3 SVD (area under the curve = 0.92). Patients with AVC > 100 AU had a worse outcome compared with those with AVC ≤ 100 AU (n = 195). In multivariable analysis, AVC was a predictor of overall mortality (hazard ratio [HR] and 95% confidence interval = 1.16 [1.04-1.29]; P = 0.006), cardiovascular mortality (HR = 1.22 [1.04-1.43]; P = 0.013), cardiovascular events (HR = 1.28 [1.16-1.41]; P < 0.0001), and re-intervention (HR = 1.15 [1.06-1.25]; P < 0.0001). After adjustment for Stage 2-3 SVD diagnosis, AVC remained a predictor of overall mortality (HR = 1.20 [1.04-1.39]; P = 0.015) and cardiovascular events (HR = 1.25 [1.09-1.43]; P = 0.001)., Conclusion: CT scan is a reliable tool to assess BP leaflet calcification. An AVC > 100 AU is tightly associated with SVD and it is a strong predictor of overall mortality and cardiovascular events., Competing Interests: Conflict of interest: T.L.T. and J.-Christ R. received a basic research grant from Abbott-St Jude company dedicated to a mitral valve prolapse project. The other authors have no disclosure., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results